Medicina clinica · 2025
Effect of cholecalciferol on 25-hydroxyvitamin D in people living with HIV and vitamin D deficiency: A prospective observational study.
СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tomás Cristina, Muñoz Ángeles, Báguena Carlos, Alcaraz Antonia, Martínez-Rodríguez Rodrigo, Hernández María Dolores, Martínez María Isabel, Corral-San-Miguel Rubén, López Eduardo Pons-Fuster, García-Villalba Eva, Valero Salvador, Galera Eva Oliver, Westermeyer Elena Guijarro, Hipólito Román González, Dólera Concepción Corbalán, Ros María Del Carmen García, Bernal Enrique
Аннотация
OBJECTIVES: To assess the effect of oral cholecalciferol 50,000IU monthly administered in people living with HIV (PLHIV) and 25(OH)D deficiency followed over 48 weeks.
METHODS: A prospective observational study was conducted in a cohort of 110 PLHIV with 25(OH)D levels<20ng/mL. Changes in 25(OH)D levels were evaluated at 3, 6, and 12 months of treatment. The percentages of patients who achieved 25(OH)D levels>20 and >30ng/mL and changes in bone mineral density (BMD) were assessed.
RESULTS: One hundred ten PLHIV (79% men, mean age 49.46 years) were included. The mean (standard deviation, SD) time on antiretroviral treatment was 10.69 (8.31) years and all patients had a viral load<50copies/mL. The mean 25(OH)D levels of 15.10±3.22ng/mL at baseline increased significantly (P<0.001) to 27.89±7.79ng/mL at 3 months, 28.53±8.45ng/mL at 6 months and 27.89±7.92ng/mL at 12 months. A total of 87.27% had normal 25(OH)D levels at 12 months (>30ng/mL in 36.1% of patients and >20ng/mL in 51.5%). Parathormone levels (PTH) also decreased significantly. Treatment was safe and well tolerated. On the other hand, no significant changes were observed in BMD.
CONCLUSIONS: Monthly administration of 50,000IU of cholecalciferol was effective in normalizing 25(OH)D deficiency in 87% of PLHIV, without observing changes in bone mineral density.
METHODS: A prospective observational study was conducted in a cohort of 110 PLHIV with 25(OH)D levels<20ng/mL. Changes in 25(OH)D levels were evaluated at 3, 6, and 12 months of treatment. The percentages of patients who achieved 25(OH)D levels>20 and >30ng/mL and changes in bone mineral density (BMD) were assessed.
RESULTS: One hundred ten PLHIV (79% men, mean age 49.46 years) were included. The mean (standard deviation, SD) time on antiretroviral treatment was 10.69 (8.31) years and all patients had a viral load<50copies/mL. The mean 25(OH)D levels of 15.10±3.22ng/mL at baseline increased significantly (P<0.001) to 27.89±7.79ng/mL at 3 months, 28.53±8.45ng/mL at 6 months and 27.89±7.92ng/mL at 12 months. A total of 87.27% had normal 25(OH)D levels at 12 months (>30ng/mL in 36.1% of patients and >20ng/mL in 51.5%). Parathormone levels (PTH) also decreased significantly. Treatment was safe and well tolerated. On the other hand, no significant changes were observed in BMD.
CONCLUSIONS: Monthly administration of 50,000IU of cholecalciferol was effective in normalizing 25(OH)D deficiency in 87% of PLHIV, without observing changes in bone mineral density.